News|Articles|August 8, 2024
Biopharmaceutical Frontiers
Author(s)Solvias
Daniel Galbraith, Chief Scientific Officer (CSO) of Solvias provided a comprehensive picture to Pharmaceutical Technology of the current landscape of cell and gene therapy advancements. The discussion covers important regulatory guidance, technological landmarks, and how Solvias is impacting the current market.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
FAQ: Key Innovations in Drug Delivery and Formulation in 2025
2
Trends and Challenges Impacting Highly Potent API Development
3
Leap Forward in Automation Anticipated for Small-Molecule Drug Product Manufacturing
4
Raman Spectroscopy—A Game-Changer in the Fight Against Counterfeit Drugs
5
